Overview

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.
Phase:
Phase 4
Details
Lead Sponsor:
American Research Corporation
Collaborator:
AbbVie
Treatments:
Ribavirin
Ritonavir